MedTrace Logo

Detection and Characterization of Residual Masses in Lymphomas

NCT02300402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-03-20

No results posted yet for this study

Summary

The present study aims to further optimize a whole-body Diffusion-Weighted Magnetic Resonance Imagery (DW-MRI or DWI) protocol on 3 Tesla MR and/or new system combining 3Tesla MR and Positron Emission Tomography (PET), to develop and validate an automated whole-body parametric image analysis algorithm, and to determine the added value of whole-body DWI to Fluorodeoxyglucose-PET for the management of lymphoma patients.

Conditions

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Alain Rahmouni, Prof. · CHU Henri Mondor

  • Corinne Haioun, Prof. · Lymphoma Study Association

  • Emmanuel Itti, Prof. · CHU Henri Mondor

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300402 on ClinicalTrials.gov